Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Per-protocol crude/unadjusted and PCR-adjusted study endpoints at days 28 and 42 of patient follow-up. Patients with re-infections and individuals for whom the outcome could not be assessed by PCR were censored from the PCR adjusted analysis

From: In vivo efficacy of artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo

Crude/no PCR Day 28 Day 42
ASAQ (n = 119) AL (n = 122) p value ASAQ (n = 119) AL (n = 119) p value
n % n % n % n %
Late clinical failure 8 6.7 4 3.3 0.250 13 10.9 10 8.4 0.510
Late parasitological failure 10 8.4 6 4.9 0.277 14 11.8 9 7.6 0.273
Adequate clinical and parasitological response 101 84.9 112 91.8 0.093 92 77.3 100 84.0 0.189
Cumulative failure 18 15.1 10 8.2 0.093 27 22.7 19 16.0 0.189
PCR adjusted/corrected Day 28 Day 42
ASAQ (n = 105)  AL (n = 111) p value ASAQ (n = 98)  AL (n = 101) p value
n % n % n % n %
Late clinical failure (recrudescence) 1 1.0 0 0 0.486 1 1.0 1 1.0 1.000
Late parasitological failure (recrudenscence) 3 2.9 0 0 0.113 5 5.1 0 0 0.027
Adequate clinical and parasitological response 101 96.2 111 100 0.038 92 93.9 100 99.0 0.049
Cumulative failure 4 3.8 0 0 0.054 6 6.1 1 1.0 0.062
  1. The analysis of the treatment outcomes by intention-to-treat are shown in Additional file 1: Annexure 1